Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-κB–mediated production of CXCL1
SB Kemp, ES Carpenter, NG Steele, KL Donahue… - Cancer research, 2021 - AACR
This study shows that elevated apolipoprotein E in PDAC mediates immune suppression
and high serum apolipoprotein E levels correlate with poor patient survival. See related …
and high serum apolipoprotein E levels correlate with poor patient survival. See related …
Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages
…, NG Steele, ES Carpenter, KL Donahue… - Life science …, 2021 - life-science-alliance.org
Pancreatic ductal adenocarcinoma (PDA) is accompanied by reprogramming of the local
microenvironment, but changes at distal sites are poorly understood. We implanted biomaterial …
microenvironment, but changes at distal sites are poorly understood. We implanted biomaterial …
Arginase 1 is a key driver of immune suppression in pancreatic cancer
RE Menjivar, ZC Nwosu, W Du, KL Donahue, HS Hong… - Elife, 2023 - elifesciences.org
An extensive fibroinflammatory stroma rich in macrophages is a hallmark of pancreatic
cancer. In this disease, it is well appreciated that macrophages are immunosuppressive and …
cancer. In this disease, it is well appreciated that macrophages are immunosuppressive and …
WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer
W Du, RE Menjivar, KL Donahue, P Kadiyala… - Journal of Experimental …, 2022 - rupress.org
Pancreatic ductal adenocarcinoma (PDA) is associated with activation of WNT signaling.
Whether this signaling pathway regulates the tumor microenvironment has remained …
Whether this signaling pathway regulates the tumor microenvironment has remained …
[HTML][HTML] Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extensive fibroinflammatory
stroma and often experiences conditions of insufficient oxygen availability or hypoxia. …
stroma and often experiences conditions of insufficient oxygen availability or hypoxia. …
Analysis of donor pancreata defines the transcriptomic signature and microenvironment of early neoplastic lesions
…, Y Zhang, J Edwards, S Nelson, F Lima, KL Donahue… - Cancer Discovery, 2023 - AACR
Precursor lesions to pancreatic cancer are poorly characterized. We analyzed donor
pancreata and discovered that precursor lesions are detected at a much higher rate than the …
pancreata and discovered that precursor lesions are detected at a much higher rate than the …
[HTML][HTML] Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
A Velez-Delgado, KL Donahue, KL Brown, W Du… - Cellular and Molecular …, 2022 - Elsevier
Background & Aims Oncogenic Kirsten Rat Sarcoma virus (KRAS) is the hallmark mutation
of human pancreatic cancer and a driver of tumorigenesis in genetically engineered mouse …
of human pancreatic cancer and a driver of tumorigenesis in genetically engineered mouse …
Notch signaling regulates immunosuppressive tumor-associated macrophage function in pancreatic cancer
…, NG Steele, SB Kemp, W Du, KL Donahue… - Cancer Immunology …, 2024 - AACR
Pancreatic ductal adenocarcinoma (PDA) continues to have a dismal prognosis. The poor
survival of patients with PDA has been attributed to a high rate of early metastasis and low …
survival of patients with PDA has been attributed to a high rate of early metastasis and low …
[HTML][HTML] Sensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction
JP Ditano, KL Donahue, LJ Tafe, CF McCleery… - Scientific Reports, 2021 - nature.com
DNA damage activates cell cycle checkpoint proteins ATR and CHK1 to arrest cell cycle
progression, providing time for repair and recovery. Consequently, inhibitors of ATR (ATRi) and …
progression, providing time for repair and recovery. Consequently, inhibitors of ATR (ATRi) and …
Differential sensitivity to CDK2 inhibition discriminates the molecular mechanisms of CHK1 inhibitors as monotherapy or in combination with the topoisomerase I …
NJH Warren, KL Donahue… - ACS Pharmacology & …, 2019 - ACS Publications
DNA damage activates checkpoints to arrest cell cycle progression in S and G2 phases,
thereby providing time for repair and recovery. The combination of DNA-damaging agents and …
thereby providing time for repair and recovery. The combination of DNA-damaging agents and …